drugset / Trial / NCT04889651

A Study to Compare the Pharmacokinetics and Safety Between BR9004 and BR9004-1 in Healthy Male Volunteers

NCT04889651

Phase 1 Completed 40 enrolled Boryung Pharmaceutical Co., Ltd
RandomizedCrossoverOpen-labelTreatment

Summary

To compare the pharmacokinetics and safety between BR9004 and BR9004-1 in healthy male subjects after a single-dose administration while fasting.

Timeline

Start
2021-04-15
Primary completion
2021-06-08
Completion
2021-06-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Abiraterone acetate Small molecule 200 mg Oral
Subject Abiraterone acetate Small molecule 500 mg Oral

Indications